Titre : Mucormycose

Mucormycose : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cognitive Dysfunction
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mucormycose : Questions médicales les plus fréquentes", "headline": "Mucormycose : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mucormycose : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-13", "dateModified": "2025-05-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mucormycose" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Zygomycose", "url": "https://questionsmedicales.fr/mesh/D020096", "about": { "@type": "MedicalCondition", "name": "Zygomycose", "code": { "@type": "MedicalCode", "code": "D020096", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C01.150.703.980" } } }, "about": { "@type": "MedicalCondition", "name": "Mucormycose", "alternateName": "Mucormycosis", "code": { "@type": "MedicalCode", "code": "D009091", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "S Sharma", "url": "https://questionsmedicales.fr/author/S%20Sharma", "affiliation": { "@type": "Organization", "name": "Medical Education Department, Jaipur, India." } }, { "@type": "Person", "name": "Hariprasath Prakash", "url": "https://questionsmedicales.fr/author/Hariprasath%20Prakash", "affiliation": { "@type": "Organization", "name": "Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. harisath2003@gmail.com." } }, { "@type": "Person", "name": "Arunaloke Chakrabarti", "url": "https://questionsmedicales.fr/author/Arunaloke%20Chakrabarti", "affiliation": { "@type": "Organization", "name": "Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. arunaloke@hotmail.com." } }, { "@type": "Person", "name": "Ilse D Jacobsen", "url": "https://questionsmedicales.fr/author/Ilse%20D%20Jacobsen", "affiliation": { "@type": "Organization", "name": "Research Group Microbial Immunology, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute (HKI), Jena, Germany. ilse.jacobsen@leibniz-hki.de." } }, { "@type": "Person", "name": "François Danion", "url": "https://questionsmedicales.fr/author/Fran%C3%A7ois%20Danion", "affiliation": { "@type": "Organization", "name": "Université Paris Descartes, Centre d'Infectiologie Necker Pasteur, IHU Imagine, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 75015 Paris, France. francois.danion@aphp.fr." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant.", "datePublished": "2022-10-17", "url": "https://questionsmedicales.fr/article/36251860", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/13506129.2022.2131384" } }, { "@type": "ScholarlyArticle", "name": "Risk factors for cognitive dysfunction amongst patients with cardiovascular diseases.", "datePublished": "2024-09-13", "url": "https://questionsmedicales.fr/article/39346594", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2024.1385089" } }, { "@type": "ScholarlyArticle", "name": "Reward network dysfunction is associated with cognitive impairment after stroke.", "datePublished": "2023-05-31", "url": "https://questionsmedicales.fr/article/37307650", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.nicl.2023.103446" } }, { "@type": "ScholarlyArticle", "name": "Predictors of cognitive dysfunction one-year post COVID-19.", "datePublished": "2023-01-05", "url": "https://questionsmedicales.fr/article/36603126", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1037/neu0000876" } }, { "@type": "ScholarlyArticle", "name": "Cognitive Dysfunction Biomarkers in Patients With Rheumatoid Arthritis: A Systematic Review.", "datePublished": "2022-12-07", "url": "https://questionsmedicales.fr/article/36729842", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/RHU.0000000000001888" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Infection", "item": "https://questionsmedicales.fr/mesh/D007239" }, { "@type": "ListItem", "position": 3, "name": "Infections bactériennes et mycoses", "item": "https://questionsmedicales.fr/mesh/D001423" }, { "@type": "ListItem", "position": 4, "name": "Mycoses", "item": "https://questionsmedicales.fr/mesh/D009181" }, { "@type": "ListItem", "position": 5, "name": "Zygomycose", "item": "https://questionsmedicales.fr/mesh/D020096" }, { "@type": "ListItem", "position": 6, "name": "Mucormycose", "item": "https://questionsmedicales.fr/mesh/D009091" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mucormycose - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mucormycose", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mucormycose", "description": "Comment diagnostique-t-on la mucormycose ?\nQuels tests sont utilisés pour confirmer la mucormycose ?\nQuels signes cliniques indiquent une mucormycose ?\nLa mucormycose peut-elle être confondue avec d'autres infections ?\nQuel rôle joue l'imagerie dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Cognitive+Dysfunction&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mucormycose", "description": "Quels sont les symptômes courants de la mucormycose ?\nLa mucormycose affecte-t-elle les poumons ?\nQuels symptômes cutanés peuvent apparaître ?\nY a-t-il des symptômes neurologiques associés ?\nComment évoluent les symptômes de la mucormycose ?", "url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Cognitive+Dysfunction&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mucormycose", "description": "Comment prévenir la mucormycose ?\nLes patients diabétiques doivent-ils être vigilants ?\nLes personnes immunodéprimées doivent-elles éviter certains environnements ?\nLes masques peuvent-ils aider à prévenir l'infection ?\nY a-t-il des vaccins contre la mucormycose ?", "url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Cognitive+Dysfunction&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mucormycose", "description": "Quel est le traitement principal de la mucormycose ?\nLa chirurgie est-elle nécessaire dans le traitement ?\nCombien de temps dure le traitement antifongique ?\nQuels sont les effets secondaires des antifongiques ?\nPeut-on utiliser des traitements alternatifs ?", "url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Cognitive+Dysfunction&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mucormycose", "description": "Quelles sont les complications possibles de la mucormycose ?\nLa mucormycose peut-elle entraîner des infections cérébrales ?\nQuels sont les risques de récidive ?\nComment la mucormycose affecte-t-elle la qualité de vie ?\nLes complications sont-elles fréquentes ?", "url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Cognitive+Dysfunction&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mucormycose", "description": "Qui est le plus à risque de mucormycose ?\nLe diabète mal contrôlé augmente-t-il le risque ?\nLes traitements immunosuppresseurs sont-ils un facteur de risque ?\nLes brûlures ou traumatismes cutanés augmentent-ils le risque ?\nL'utilisation prolongée de corticostéroïdes est-elle risquée ?", "url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Cognitive+Dysfunction&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on la mucormycose ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique, l'imagerie et la culture fongique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer la mucormycose ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent des biopsies, des cultures et des examens d'imagerie comme l'IRM." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une mucormycose ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des douleurs faciales, des écoulements nasaux et des lésions cutanées." } }, { "@type": "Question", "name": "La mucormycose peut-elle être confondue avec d'autres infections ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être confondue avec d'autres mycoses ou infections bactériennes." } }, { "@type": "Question", "name": "Quel rôle joue l'imagerie dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie aide à visualiser l'étendue de l'infection et à guider le traitement." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de la mucormycose ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, douleur faciale, congestion nasale et vision floue." } }, { "@type": "Question", "name": "La mucormycose affecte-t-elle les poumons ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des symptômes respiratoires comme la toux et la dyspnée." } }, { "@type": "Question", "name": "Quels symptômes cutanés peuvent apparaître ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des lésions cutanées, des ulcères et des nécroses peuvent se développer." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maux de tête, des troubles de la conscience et des convulsions peuvent survenir." } }, { "@type": "Question", "name": "Comment évoluent les symptômes de la mucormycose ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent s'aggraver rapidement, nécessitant une intervention urgente." } }, { "@type": "Question", "name": "Comment prévenir la mucormycose ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut le contrôle des facteurs de risque et une bonne hygiène." } }, { "@type": "Question", "name": "Les patients diabétiques doivent-ils être vigilants ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un contrôle strict de la glycémie est crucial pour prévenir la mucormycose." } }, { "@type": "Question", "name": "Les personnes immunodéprimées doivent-elles éviter certains environnements ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, éviter les environnements humides et les zones de champignons est recommandé." } }, { "@type": "Question", "name": "Les masques peuvent-ils aider à prévenir l'infection ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Les masques peuvent réduire l'exposition aux spores fongiques dans certains environnements." } }, { "@type": "Question", "name": "Y a-t-il des vaccins contre la mucormycose ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccin spécifique contre la mucormycose." } }, { "@type": "Question", "name": "Quel est le traitement principal de la mucormycose ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal est l'administration d'antifongiques comme l'amphotéricine B." } }, { "@type": "Question", "name": "La chirurgie est-elle nécessaire dans le traitement ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la débridement chirurgical peut être nécessaire pour enlever les tissus nécrosés." } }, { "@type": "Question", "name": "Combien de temps dure le traitement antifongique ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut durer plusieurs semaines, selon la gravité de l'infection." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des antifongiques ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des troubles rénaux et des réactions allergiques." } }, { "@type": "Question", "name": "Peut-on utiliser des traitements alternatifs ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements alternatifs ne sont pas recommandés sans avis médical, car ils peuvent être inefficaces." } }, { "@type": "Question", "name": "Quelles sont les complications possibles de la mucormycose ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la perte de vision, des infections systémiques et la mort." } }, { "@type": "Question", "name": "La mucormycose peut-elle entraîner des infections cérébrales ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des infections cérébrales graves comme la rhinocéphalite." } }, { "@type": "Question", "name": "Quels sont les risques de récidive ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les patients immunodéprimés ont un risque élevé de récidive après traitement." } }, { "@type": "Question", "name": "Comment la mucormycose affecte-t-elle la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut gravement affecter la qualité de vie en raison des séquelles physiques et psychologiques." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications sont fréquentes chez les patients à haut risque, surtout sans traitement rapide." } }, { "@type": "Question", "name": "Qui est le plus à risque de mucormycose ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes immunodéprimées, diabétiques ou ayant subi une transplantation sont à risque." } }, { "@type": "Question", "name": "Le diabète mal contrôlé augmente-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un diabète mal contrôlé est un facteur de risque majeur pour la mucormycose." } }, { "@type": "Question", "name": "Les traitements immunosuppresseurs sont-ils un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements immunosuppresseurs augmentent le risque d'infections fongiques comme la mucormycose." } }, { "@type": "Question", "name": "Les brûlures ou traumatismes cutanés augmentent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les blessures cutanées peuvent servir de porte d'entrée pour l'infection fongique." } }, { "@type": "Question", "name": "L'utilisation prolongée de corticostéroïdes est-elle risquée ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'utilisation prolongée de corticostéroïdes peut affaiblir le système immunitaire et augmenter le risque." } } ] } ] }

Sources (10000 au total)

Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant.

Cognitive dysfunction is part of the broad spectrum of clinical manifestations in older untreated hereditary transthyretin amyloidosis patients with peripheral polyneuropathy.... The objective of this study is to systematically explore cognitive dysfunction in ATTRV30M amyloidosis patients whose disease course was modified by liver transplant (LT).... A series of 269 carriers of TTRVal30Met mutation treated with LT underwent a neuropsychological assessment. Clinical charts were reviewed to identify focal neurological episodes (FNEs), cognitive comp... Cognitive dysfunction was identified in 35 patients (13%)-14 (5%) had mild and 21 (8%) had moderate dysfunction. In comparison to normal cognition, both mild and moderate cognitive dysfunction patient... Consistent with the natural history of the disease, older age and higher severity of the disease are significantly associated and potentially predictors of cognitive dysfunction in ATTRV30M patients t...

Risk factors for cognitive dysfunction amongst patients with cardiovascular diseases.

The impact of cardiovascular diseases on cognition raises important research questions. The study aimed to investigate the relationship between demographic data, cardiovascular diseases, kidney diseas... A cross-sectional study of patients with cardiovascular diseases was performed. The Montreal Cognitive Assessment (MoCA) was applied for cognitive evaluation. Based on MoCA three groups were defined: ... Of 628 patients, 55.2% had mild CD, and the mean age was 67.95 (SD 9.53) years. Cα and Mω were 0.7, indicating good internal consistency. We found a moderate positive correlation between depression an... Mild CD was the most common in patients with cardiovascular diseases. Older age, lower education, being a non-smoker, and renal dysfunction were risk factors for both mild and advanced CD. Female gend...

Predictors of cognitive dysfunction one-year post COVID-19.

(a) To characterize the frequency of objective cognitive deficits and self-perceived cognitive difficulties and (b) to explore demographic and clinical predictors of cognitive dysfunction and cognitiv... One hundred and ten adults diagnosed with COVID-19 between March and November 2020, aged ≤ 74 years underwent a brief neuropsychological evaluation 12 months after infection, which included: Brief Vis... Twenty participants (18.2%) had cognitive dysfunction and 36 (33.3%) had cognitive complaints. Cognitive dysfunction was related to lower education, preinfection history of headache/migraine, and acut... A subset of individuals develops cognitive difficulties in the context of post-COVID syndrome. Results may support the protective effect of education, a known proxy of cognitive reserve. COVID-19 infe...

Cognitive Dysfunction Biomarkers in Patients With Rheumatoid Arthritis: A Systematic Review.

During the last years, a growing number of studies have investigated the link between cognitive dysfunction and rheumatoid arthritis (RA), highlighting the potential pathogenic role of several clinica... We performed a systematic review using PRISMA (Preferred Reported Items for Systematic Reviews and Meta-analysis) protocol. A systematic search was conducted in the PubMed/MEDLINE, EMBASE, LILACS, Sco... Five original studies were included, which provided data from 428 participants. Among plasma proteins, SHH was increased and TTR was reduced in patients with mild cognitive impairment; anti-myelin bas... Despite the relative scarcity of studies on this subject and the heterogeneity of results, we identified possible biomarkers for cognitive deficits in the RA population. Further longitudinal studies a...

Endothelial Dysfunction and Pre-Existing Cognitive Disorders in Stroke Patients.

The origin of pre-existing cognitive impairment in stroke patients remains controversial, with a vascular or a degenerative hypothesis.... To determine whether endothelial dysfunction is associated with pre-existing cognitive problems, lesion load and biological anomalies in stroke patients.... Patients originated from the prospective STROKDEM study. The baseline cognitive state, assessed using the IQ-CODE, and risk factors for stroke were recorded at inclusion. Patients with an IQ-CODE scor... A total of 86 patients were included (52 males; mean age 63.5 ± 11.5 years). Patients with abnormal RHI have hypertension or antihypertensive treatment more often. The baseline IQ-CODE was abnormal in... A vascular mechanism may be responsible for cognitive problems pre-existing stroke. The measurement of endothelial dysfunction after stroke could become an important element of follow-up, providing an...

Cognitive Dysfunction in Heart Failure: Pathophysiology and Implications for Patient Management.

There is increasing recognition of the prevalence and impact of cognitive dysfunction (CD) in heart failure (HF) patients. This contemporary review appraises the evidence for epidemiological associati... CD disproportionately affects heart failure patients, even accounting for known comorbid risk factors, and this may extend to subclinical left ventricular dysfunction. Neuroimaging studies now provide...

Frequency and risk factors for cognitive dysfunction in peritoneal dialysis patients.

There is limited data on cognition in patients undergoing peritoneal dialysis (PD). We assessed prevalence and associated risk factors of neurocognitive impairment (NCI) in PD patients.... A cross-sectional cohort study of 149 PD patients at a single centre between 2016 and 2020 who underwent neurocognitive screening at defined intervals by Addenbrooke's Cognitive Examination - Revised ... Patients on PD performed poorly in ACE-R screening compared to population norms, with discrepancy in all cognitive domains. In patients without CVD, attention and language domains were comparable to n... Patients on PD have higher prevalence of NCI than the general population, primarily with impairments in memory, fluency and visuospatial reasoning. CVD confers poorer performance in attention and lang...